Gabriela Calamante
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gabriela Calamante has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- María Paula Del Médico Zajac
Instituto de Agrobiotecnología y Biología Molecular (IABiMo), Instituto Nacional de Tecnología Agropecuaria (INTA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Nicolás Repetto y De Los Reseros S/N, Hurlingham B1686IGC, Buenos Aires, Argentina
10 shared publications Débora Garanzini
Consejo Nacl Invest Cient & Tecn CONICET, Inst Nacl Tecnol Agr INTA, Inst Agrobiotecnol & Biol Mol IABiMo, Nicolas Repetto & De Los Reseros S-N,B1686IGC, Hurlingham, Buenos Aires, Argentina
3 shared publicationsFlavia Adriana Zanetti
Instituto de Biotecnología, Instituto Nacional de Tecnología Agropecuaria (CICVyA-INTA) , Hurlingham, Argentina
3 shared publications- Annalies Torres Lopez
Instituto de Agrobiotecnología y Biología Molecular (IABiMo), Instituto Nacional de Tecnología Agropecuaria (INTA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Nicolás Repetto y De Los Reseros S/N, Hurlingham B1686IGC, Buenos Aires, Argentina
2 shared publications Carlos Rodolfo Federico
Instituto de Biotecnología, Instituto Nacional de Tecnología Agropecuaria (CICVyA-INTA) , Hurlingham, Argentina
2 shared publications- Debora Patricia Garanzini
Instituto de Agrobiotecnología y Biología Molecular (IABiMo), Instituto Nacional de Tecnología Agropecuaria (INTA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Nicolás Repetto y De Los Reseros S/N, Hurlingham B1686IGC, Buenos Aires, Argentina
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7827
Targeting Latent Tuberculosis: Immunogenic Evaluation of a Mycobacterium tuberculosis Dormancy Antigen as a Vaccine Candidate
An estimated 2.1 billion people are infected with Mycobacterium tuberculosis (Mtb) and at risk of developing active tuberculosis (TB). Because Mtb exists in replicating and dormant states, effective vaccines should target antigens from both stages. Here, we evaluated the immunogenicity and vaccine potential of Mtb dormancy antigen Rv2626c. Cellular and humoral immune responses were studied in individuals with latent TB infection (LTBI), active TB, and healthy donors (HD) using flow cytometry and ELISA. Overlapping peptides spanning Rv2626c sequence and structural mapping were employed to characterize Rv2626c immunogenic regions. Additionally, the protective efficacy of a Modified Vaccinia Ankara (MVA) vector expressing Rv2626c was evaluated in a murine challenge model. Rv2626c induced cellular immunity selectively in LTBI, characterized by increased frequencies of CD4+IFN-γ+, SLAMF1+, and poly-functional T lymphocytes. Immunodominant peptide regions were identified across the protein sequence. Moreover, mice immunized with MVA-Rv2626c showed a significant reduction in splenic bacterial burden following a challenge with Mtb H37Rv. Altogether, our findings indicate that the latency-associated antigen Rv2626c elicits immune responses in LTBI subjects and limits bacterial dissemination in our mice model of infection. Therefore, Rv2626c arises as a promising candidate to be combined with active phase antigens in multistage vaccines against Mtb infection.
- 1 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7827
Open AccessTargeting Latent Tuberculosis: Immunogenic Evaluation of a Mycobacterium tuberculosis Dormancy Antigen as a Vaccine Candidate
An estimated 2.1 billion people are infected with Mycobacterium tuberculosis (Mtb) and at risk of developing active tuberculosis (TB). Because Mtb exists in replicating and dormant states, effective vaccines should target antigens from both stages. Here, we evaluated the immunogenicity and vaccine potential of Mtb dormancy antigen Rv2626c. Cellular and humoral immune responses were studied in individuals with latent TB infection (LTBI), active TB, and healthy donors (HD) using flow cytometry and ELISA. Overlapping peptides spanning Rv2626c sequence and structural mapping were employed to characterize Rv2626c immunogenic regions. Additionally, the protective efficacy of a Modified Vaccinia Ankara (MVA) vector expressing Rv2626c was evaluated in a murine challenge model. Rv2626c induced cellular immunity selectively in LTBI, characterized by increased frequencies of CD4+IFN-γ+, SLAMF1+, and poly-functional T lymphocytes. Immunodominant peptide regions were identified across the protein sequence. Moreover, mice immunized with MVA-Rv2626c showed a significant reduction in splenic bacterial burden following a challenge with Mtb H37Rv. Altogether, our findings indicate that the latency-associated antigen Rv2626c elicits immune responses in LTBI subjects and limits bacterial dissemination in our mice model of infection. Therefore, Rv2626c arises as a promising candidate to be combined with active phase antigens in multistage vaccines against Mtb infection.
- Open Access
Protection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein
Rabies is a zoonotic viral disease that is preventable through vaccination. Effective control strategies should follow the “One Health” concept, as targeting zoonotic pathogens at their animal source is the most effective and cost-efficient approach to protecting human health. The aim of this study was to develop and evaluate two third-generation anti-rabies vaccines based on non-replicative viral vectors, MVA and Ad5, both expressing rabies virus (RABV) glycoprotein (MVA-RG and Ad-RG). MVA-RG was produced using a platform developed in our laboratory, while Ad-RG was generated using a commercial kit. Protection against rabies was assessed in a mouse intracerebral (IC) RABV challenge model. Our results demonstrated that both vectors provided protection against RABV. MVA-RG and Ad-RG administered in two homologous doses conferred 60% and 60–100% protection against RABV challenge, respectively. The survival rate was influenced by the viral vector, the dose, and the immunization scheme. Remarkably, to our knowledge, our study is the first to report 100% protection against IC RABV challenge using a non-replicative Ad5 in a homologous immunization scheme. These promising results support future evaluation of this vaccine candidate in target animals.
Open AccessProtection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein
Rabies is a zoonotic viral disease that is preventable through vaccination. Effective control strategies should follow the “One Health” concept, as targeting zoonotic pathogens at their animal source is the most effective and cost-efficient approach to protecting human health. The aim of this study was to develop and evaluate two third-generation anti-rabies vaccines based on non-replicative viral vectors, MVA and Ad5, both expressing rabies virus (RABV) glycoprotein (MVA-RG and Ad-RG). MVA-RG was produced using a platform developed in our laboratory, while Ad-RG was generated using a commercial kit. Protection against rabies was assessed in a mouse intracerebral (IC) RABV challenge model. Our results demonstrated that both vectors provided protection against RABV. MVA-RG and Ad-RG administered in two homologous doses conferred 60% and 60–100% protection against RABV challenge, respectively. The survival rate was influenced by the viral vector, the dose, and the immunization scheme. Remarkably, to our knowledge, our study is the first to report 100% protection against IC RABV challenge using a non-replicative Ad5 in a homologous immunization scheme. These promising results support future evaluation of this vaccine candidate in target animals.
- Open Access
- 27 December 2024
- Published by MDPI AG in Preprints.org
Protection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein
Rabies is a zoonotic viral disease preventable through vaccination. Control strategies should be based on the “One Health” concept, as addressing zoonotic pathogens at their animal source is the most effective and cost-efficient approach to protect human health. The aim of this study was to develop two third-generation anti-rabies vaccines based on non-replicative viral vectors, MVA and Ad5, expressing rabies virus (RABV) glycoprotein (MVA-RG and Ad-RG), and to evaluate their efficacy in an intracerebral RABV challenge model. MVA-RG was produced using a platform developed in our laboratory, while a commercial kit was used to produce Ad-RG. Protection against rabies was assessed in a mouse intracerebral challenge model. Our results demonstrated that both non-replicative viral vectors provided protection against RABV. The MVA-RG and Ad-RG vectors, administered in two homologous doses, conferred 60% and 60-100% protection against RABV challenge, respectively. The survival rate was influenced by the type of viral vector, the administered dose, and the immunization scheme applied. Remarkably, to our knowledge, our study is the first to report 100% protection against RABV IC challenge using non-replicative Ad5 in a homologous immunization scheme. These results encourage us to proceed with the evaluation of this vaccine candidate in target animals.
- 27 December 2024
- Published by MDPI AG in Preprints.org
Open AccessProtection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein
Rabies is a zoonotic viral disease preventable through vaccination. Control strategies should be based on the “One Health” concept, as addressing zoonotic pathogens at their animal source is the most effective and cost-efficient approach to protect human health. The aim of this study was to develop two third-generation anti-rabies vaccines based on non-replicative viral vectors, MVA and Ad5, expressing rabies virus (RABV) glycoprotein (MVA-RG and Ad-RG), and to evaluate their efficacy in an intracerebral RABV challenge model. MVA-RG was produced using a platform developed in our laboratory, while a commercial kit was used to produce Ad-RG. Protection against rabies was assessed in a mouse intracerebral challenge model. Our results demonstrated that both non-replicative viral vectors provided protection against RABV. The MVA-RG and Ad-RG vectors, administered in two homologous doses, conferred 60% and 60-100% protection against RABV challenge, respectively. The survival rate was influenced by the type of viral vector, the administered dose, and the immunization scheme applied. Remarkably, to our knowledge, our study is the first to report 100% protection against RABV IC challenge using non-replicative Ad5 in a homologous immunization scheme. These results encourage us to proceed with the evaluation of this vaccine candidate in target animals.
- Open Access
- 23 December 2023
- Published by Elsevier in Revista Argentina de Microbiologia
- Vol. 56 (2) , 125-133
The MVA vector expressing the F protein of bovine respiratory syncytial virus is immunogenic in systemic and mucosal immunization routes
- 23 December 2023
- Published by Elsevier in Revista Argentina de Microbiologia
- Vol. 56 (2) , 125-133
Open AccessThe MVA vector expressing the F protein of bovine respiratory syncytial virus is immunogenic in systemic and mucosal immunization routes
- Open Access
- 23 September 2020
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 10
IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations
Mycobacterium tuberculosis (Mtb) infection is one of the leading causes of death worldwide. The Modified Vaccinia Ankara (MVA) vaccine vector expressing the mycobacterial antigen 85A (MVA85A) was demonstrated to be safe, although it did not improve BCG efficacy, denoting the need to search for improved tuberculosis vaccines. In this work, we investigated the effect of IL-12 DNA -as an adjuvant- on an Ag85A DNA prime/MVA85A boost vaccination regimen. We evaluated the immune response profile elicited in mice and the protection conferred against intratracheal Mtb H37Rv challenge. We observed that the immunization scheme including DNA-A85A+DNA-IL-12/MVA85A induced a strong IFN-γ production to Ag85A in vitro, with a significant expansion of IFN-γ+CD4+ and IFN-γ+CD8+ anti-Ag85A lymphocytes. Furthermore, we also detected a significant increase in the proportion of specific CD8+CD107+ T cells against Ag85A. Additionally, inclusion of IL-12 DNA in the DNA-A85A/MVA85A vaccine scheme induced a marked augment in anti-Ag85A IgG levels. Interestingly, after 30 days of infection with Mtb H37Rv, DNA-A85A+DNA-IL-12/MVA85A vaccinated mice displayed a significant reduction in lung bacterial burden. Together, our findings suggest that IL-12 DNA might be useful as a molecular adjuvant in an Ag85A DNA/MVA prime-boost vaccine against Mtb infection.
- 23 September 2020
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 10
Open AccessIL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations
Mycobacterium tuberculosis (Mtb) infection is one of the leading causes of death worldwide. The Modified Vaccinia Ankara (MVA) vaccine vector expressing the mycobacterial antigen 85A (MVA85A) was demonstrated to be safe, although it did not improve BCG efficacy, denoting the need to search for improved tuberculosis vaccines. In this work, we investigated the effect of IL-12 DNA -as an adjuvant- on an Ag85A DNA prime/MVA85A boost vaccination regimen. We evaluated the immune response profile elicited in mice and the protection conferred against intratracheal Mtb H37Rv challenge. We observed that the immunization scheme including DNA-A85A+DNA-IL-12/MVA85A induced a strong IFN-γ production to Ag85A in vitro, with a significant expansion of IFN-γ+CD4+ and IFN-γ+CD8+ anti-Ag85A lymphocytes. Furthermore, we also detected a significant increase in the proportion of specific CD8+CD107+ T cells against Ag85A. Additionally, inclusion of IL-12 DNA in the DNA-A85A/MVA85A vaccine scheme induced a marked augment in anti-Ag85A IgG levels. Interestingly, after 30 days of infection with Mtb H37Rv, DNA-A85A+DNA-IL-12/MVA85A vaccinated mice displayed a significant reduction in lung bacterial burden. Together, our findings suggest that IL-12 DNA might be useful as a molecular adjuvant in an Ag85A DNA/MVA prime-boost vaccine against Mtb infection.
- 20 September 2019
- Published by Elsevier
- p. 225-242
Recombinant Veterinary Vaccines Against Rabies: State of Art and Perspectives
- 20 September 2019
- Published by Elsevier
- p. 225-242
Recombinant Veterinary Vaccines Against Rabies: State of Art and Perspectives
- 4 April 2017
- Published by Springer Nature
- Vol. 1581, 15-28
Development of Recombinant Canarypox Viruses Expressing Immunogens
Canarypox viruses (CNPV) are excellent candidates to develop recombinant vector vaccines due to both their capability to induce protective immune responses and their incompetence to replicate in mammalian cells (safety profile). In addition, CNPV and the derived recombinants can be manipulated under biosafety level 1 conditions. There is no commercially available system to obtain recombinant CNPV; however, the methodology and tools required to develop recombinant vaccinia virus (VV), prototype of the Poxviridae family, can be easily adapted. This chapter provides protocols for the generation, plaque isolation, molecular characterization, amplification and purification of recombinant CNPV.
- 4 April 2017
- Published by Springer Nature
- Vol. 1581, 15-28
Development of Recombinant Canarypox Viruses Expressing Immunogens
Canarypox viruses (CNPV) are excellent candidates to develop recombinant vector vaccines due to both their capability to induce protective immune responses and their incompetence to replicate in mammalian cells (safety profile). In addition, CNPV and the derived recombinants can be manipulated under biosafety level 1 conditions. There is no commercially available system to obtain recombinant CNPV; however, the methodology and tools required to develop recombinant vaccinia virus (VV), prototype of the Poxviridae family, can be easily adapted. This chapter provides protocols for the generation, plaque isolation, molecular characterization, amplification and purification of recombinant CNPV.